- Home
- ROC vs HURA Comparison
ROC vs HURA Comparison
Compare ROC & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ROC | HURA |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | 82 | 22 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.3M | 144.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROC | HURA |
|---|---|---|
| Price | $6.36 | $3.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.00 | ★ $10.00 |
| AVG Volume (30 Days) | 29.8K | ★ 958.9K |
| Earning Date | 05-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.15 | $0.41 |
| 52 Week High | $7.80 | $4.41 |
Technical Indicators
Market Signals| Indicator | ROC | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 78.19 |
| Support Level | $5.65 | $2.27 |
| Resistance Level | $7.43 | $3.30 |
| Average True Range (ATR) | 0.64 | 0.27 |
| MACD | -0.13 | 0.12 |
| Stochastic Oscillator | 35.50 | 97.64 |
Price Performance
Historical ComparisonAbout ROC Rank One Computing Corporation Common stock
Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.